bioAffinity Technologies is a company focusing on the diagnosis of early-stage cancer, diseases of the lung, and targeted cancer treatment. It offers a proprietary platform, CyPath, for in vitro diagnostics, and a noninvasive test for early detection of lung cancer called CyPath Lung.